Johnson & Johnson sees Alios BioPharma Inc. as a perfect fit for advancing its anti-infective drug-development strategy, with a Phase II candidate for respiratory syncytial virus and a pair of preclinical hepatitis C compounds that bolster the commercial viability of the pharma’s hepatitis C blockbuster Olysio (simeprevir).
The twin primary areas of focus for Janssen Pharmaceutical Cos.’s drug development strategy in infectious diseases are respiratory infection and hepatitis, William Hait, global head of R&D for the...